Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Christopher Lieu to Female

This is a "connection" page, showing publications Christopher Lieu has written about Female.

 
Connection Strength
  
 
 
0.460
  
  1. Lieu CH, Lenz HJ, Benson AB, Meng X, Kim UI, Kim SH, Kim K, Sung MJ. A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors. Cancer Res Commun. 2025 Oct 01; 5(10):1771-1778.
    View in: PubMed
    Score: 0.032
  2. Lentz RW, Hu J, Robinson H, Balmaceda N, Baiyee E, Leal AD, Kim SS, Davis SL, Messersmith WA, Lieu CH. Real-World Analysis of Irinotecan With or Without Fluorouracil in the Second-Line Treatment of Metastatic Colorectal Cancer. J Natl Compr Canc Netw. 2025 08; 23(8).
    View in: PubMed
    Score: 0.032
  3. Lentz RW, Friedrich TJ, Blatchford PJ, Jordan KR, Pitts TM, Robinson HR, Davis SL, Kim SS, Leal AD, Lee MR, Waring MRN, Martin AC, Dominguez ATA, Bagby SM, Hartman SJ, Eckhardt SG, Messersmith WA, Lieu CH. A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer. Clin Cancer Res. 2024 Sep 03; 30(17):3768-3778.
    View in: PubMed
    Score: 0.030
  4. Leary JB, Hu J, Leal A, Davis SL, Kim S, Lentz R, Friedrich T, Herter W, Messersmith WA, Lieu CH. Risk Without Reward: Differing Patterns of Chemotherapy Use Do Not Improve Outcomes in Stage II Early-Onset Colon Cancer. JCO Oncol Pract. 2025 Mar; 21(3):333-340.
    View in: PubMed
    Score: 0.030
  5. Lieu CH, Golemis EA, Serebriiskii IG, Newberg J, Hemmerich A, Connelly C, Messersmith WA, Eng C, Eckhardt SG, Frampton G, Cooke M, Meyer JE. Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer. Clin Cancer Res. 2019 10 01; 25(19):5852-5858.
    View in: PubMed
    Score: 0.021
  6. Krishnamurthy A, Dasari A, Noonan AM, Mehnert JM, Lockhart AC, Leong S, Capasso A, Stein MN, Sanoff HK, Lee JJ, Hansen A, Malhotra U, Rippke S, Gustafson DL, Pitts TM, Ellison K, Davis SL, Messersmith WA, Eckhardt SG, Lieu CH. Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res. 2018 09 15; 78(18):5398-5407.
    View in: PubMed
    Score: 0.020
  7. Lieu CH, Hidalgo M, Berlin JD, Ko AH, Cervantes A, LoRusso P, Gerber DE, Eder JP, Eckhardt SG, Kapp AV, Tsuhako A, McCall B, Pirzkall A, Uyei A, Tabernero J. A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. Oncologist. 2017 09; 22(9):1024-e89.
    View in: PubMed
    Score: 0.018
  8. Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, Saltz L, Goldberg RM, Sargent DJ, Eckhardt SG, Eng C. Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. J Clin Oncol. 2014 Sep 20; 32(27):2975-84.
    View in: PubMed
    Score: 0.015
  9. Dorstyn D, Roberts R, Kneebone I, Kennedy P, Lieu C. Systematic review of leisure therapy and its effectiveness in managing functional outcomes in stroke rehabilitation. Top Stroke Rehabil. 2014 Jan-Feb; 21(1):40-51.
    View in: PubMed
    Score: 0.014
  10. Lieu CH, Tran H, Jiang ZQ, Mao M, Overman MJ, Lin E, Eng C, Morris J, Ellis L, Heymach JV, Kopetz S. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One. 2013; 8(10):e77117.
    View in: PubMed
    Score: 0.014
  11. Lieu CH, Lambert LA, Wolff RA, Eng C, Zhang N, Wen S, Rafeeq S, Taggart M, Fournier K, Royal R, Mansfield P, Overman MJ. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol. 2012 Mar; 23(3):652-658.
    View in: PubMed
    Score: 0.012
  12. Lieu C, Chow L, Pierson AS, Eckhardt SG, O'Bryant CL, Morrow M, Tran ZV, Wright JJ, Gore L. A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy. Invest New Drugs. 2009 Feb; 27(1):53-62.
    View in: PubMed
    Score: 0.010
  13. Lieu CH, Wu HS, Hon YC, Tsai WH, Yang CF, Wang CC, Lin YC, Shih CH, Hsu HC. Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders. Intern Med J. 2008 Jun; 38(6):422-6.
    View in: PubMed
    Score: 0.010
  14. Sinicrope FA, Ou FS, Arnold D, Peters WR, Behrens RJ, Lieu CH, Matin K, Cohen DJ, Potter SL, Nixon AB, Kottschade LA, Kathol E, Frankel WL, Shergill A, Hsu D, Reinacher-Schick A, Mehan P, Gold PJ, Khalil MF, Zemla T, Gatten C, O'Reilly EM, Meyerhardt JA. Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2026 Mar 26; 394(12):1155-1166.
    View in: PubMed
    Score: 0.008
  15. Uprety D, Sweeney K, Arjyal L, Hadid T, Shields A, Lieu C, Huey R, Raghav K, Elliott A, Fountain MD, Oberley MJ, Subbiah V, Seeber A. Real-World Biomarker-Associated Therapy in Metastatic Carcinoma of Unknown Primary: Prevalence, Impact, and Outcomes. J Natl Compr Canc Netw. 2026 Mar 24; 24(4).
    View in: PubMed
    Score: 0.008
  16. Morris VK, Ciombor KK, Xiao L, Ochieng JK, Marmonti E, Polite B, Weinberg BA, Krauss JC, Hays J, Mukherjee S, Aranha O, Iqbal S, Shields T, Benson AB, Kazmi S, Lieu C, Hochster H, Whisenant J, Haymaker C, Eng C. NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal. J Clin Oncol. 2026 Feb 20; 44(6):497-507.
    View in: PubMed
    Score: 0.008
  17. Lentz RW, Lang J, Pitts TM, Blatchford P, Hu J, Jordan KR, Van Bokhoven A, Bagby SM, Dominguez ATA, Binns CA, Robinson HR, Balmaceda N, Baiyee E, Leal AD, Kim SS, Davis SL, Lieu CH, Wadlow RC, Spencer K, Scott AJ, Boland PM, Hochster HS, Messersmith WA. Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer. Cancer Res Commun. 2025 Nov 01; 5(11):2039-2052.
    View in: PubMed
    Score: 0.008
  18. Robinson HR, Lakritz S, Pavlick DC, Davis SL, Lieu CH, Eule CJ, Graham LS, Spiess PE, Li R, Kamat AM, Grivas P, Jacob JM, Bratslavsky G, Basnet A, Wong KA, Lin DI, Necchi A, Ross JS, Lam ET. Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study. ESMO Open. 2025 Jun; 10(6):105312.
    View in: PubMed
    Score: 0.008
  19. Zimmaro LA, Christie AJ, Altman JK, Nicklawsky A, Carson JW, Lieu C, Fang C, Reese JB. Body compassion in the context of cancer: A novel exploration among colorectal cancer survivors. Support Care Cancer. 2024 Nov 28; 32(12):830.
    View in: PubMed
    Score: 0.008
  20. Ueberroth BE, Lieu CH, Lentz RW. Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation. J Gastrointest Cancer. 2024 Sep; 55(3):1448-1452.
    View in: PubMed
    Score: 0.007
  21. Segal NH, Melero I, Moreno V, Steeghs N, Marabelle A, Rohrberg K, Rodriguez-Ruiz ME, Eder JP, Eng C, Manji GA, Waterkamp D, Leutgeb B, Bouseida S, Flinn N, Das Thakur M, Elze MC, Koeppen H, Jamois C, Martin-Facklam M, Lieu CH, Calvo E, Paz-Ares L, Tabernero J, Argilés G. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials. Nat Commun. 2024 May 15; 15(1):4091.
    View in: PubMed
    Score: 0.007
  22. Demb J, Kolb JM, Dounel J, Fritz CDL, Advani SM, Cao Y, Coppernoll-Blach P, Dwyer AJ, Perea J, Heskett KM, Holowatyj AN, Lieu CH, Singh S, Spaander MCW, Vuik FER, Gupta S. Red Flag Signs and Symptoms for Patients With Early-Onset Colorectal Cancer: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2024 05 01; 7(5):e2413157.
    View in: PubMed
    Score: 0.007
  23. Chen EX, Kavan P, Tehfe M, Kortmansky JS, Sawyer MB, Chiorean EG, Lieu CH, Polite B, Wong L, Fakih M, Spencer K, Chaves J, Li C, Leconte P, Adelberg D, Kim R. Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E. Clin Colorectal Cancer. 2024 Jun; 23(2):183-193.
    View in: PubMed
    Score: 0.007
  24. Kim R, Tehfe M, Kavan P, Chaves J, Kortmansky JS, Chen EX, Lieu CH, Wong L, Fakih M, Spencer K, Zhao Q, Predoiu R, Li C, Leconte P, Adelberg D, Chiorean EG. Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D. Clin Colorectal Cancer. 2024 Jun; 23(2):118-127.e6.
    View in: PubMed
    Score: 0.007
  25. Amo-Aparicio J, Dominguez A, Atif SM, Dinarello A, Azam T, Alula KM, Piper M, Lieu CH, Lentz RW, Leal AD, Bagby SM, Messersmith WA, Karam SD, Dinarello CA, Pitts TM, Marchetti C. Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment. Cancer Res Commun. 2023 09 20; 3(9):1899-1911.
    View in: PubMed
    Score: 0.007
  26. Moyer AM, Madsen H, Johnson J, Del Chiaro M, Gleisner A, Lieu CH, Tevis S, Stewart CL. Informational Needs of Surgical Oncology Patients: A Cross-Sectional Patient Survey. J Surg Res. 2023 Mar; 283:771-777.
    View in: PubMed
    Score: 0.007
  27. Chapman BC, Lai SH, Friedrich T, Lieu CH, Moskalenko M, Olsen JR, Herter W, Birnbaum EH, McCarter MD, Vogel JD. Rectal Cancer: Clinical and Molecular Predictors of a Complete Response to Total Neoadjuvant Therapy. Dis Colon Rectum. 2023 04 01; 66(4):521-530.
    View in: PubMed
    Score: 0.006
  28. Oba A, Wu YHA, Lieu CH, Meguid C, Colborn KL, Beaty L, Al-Musawi MH, Davis SL, Leal AD, Purcell T, King G, Wooten ES, Fujiwara Y, Goodman KA, Schefter T, Karam SD, Gleisner AL, Ahrendt S, Leong S, Messersmith WA, Schulick RD, Del Chiaro M. Outcome of neoadjuvant treatment for pancreatic cancer in elderly patients: comparative, observational cohort study. Br J Surg. 2021 08 19; 108(8):976-982.
    View in: PubMed
    Score: 0.006
  29. Han S, Kolb JM, Hosokawa P, Friedman C, Fox C, Scott FI, Lieu CH, Vajravelu RK, McCarter M, Murphy CC, Cook MB, Gleisner A, Falk GW, Katzka DA, Wani S. The Volume-Outcome Effect Calls for Centralization of Care in Esophageal Adenocarcinoma: Results From a Large National Cancer Registry. Am J Gastroenterol. 2021 04; 116(4):811-815.
    View in: PubMed
    Score: 0.006
  30. Kopetz S, Guthrie KA, Morris VK, Lenz HJ, Magliocco AM, Maru D, Yan Y, Lanman R, Manyam G, Hong DS, Sorokin A, Atreya CE, Diaz LA, Allegra C, Raghav KP, Wang SE, Lieu CH, McDonough SL, Philip PA, Hochster HS. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). J Clin Oncol. 2021 02 01; 39(4):285-294.
    View in: PubMed
    Score: 0.006
  31. Holowatyj AN, Langston ME, Han Y, Viskochil R, Perea J, Cao Y, Rogers CR, Lieu CH, Moore JX. Community Health Behaviors and Geographic Variation in Early-Onset Colorectal Cancer Survival Among Women. Clin Transl Gastroenterol. 2020 12; 11(12):e00266.
    View in: PubMed
    Score: 0.006
  32. Moroney JW, Powderly J, Lieu CH, Bendell JC, Eckhardt SG, Chang CW, Molinero L, Spahn J, Williams P, Lin YG, Hodi FS. Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study. Clin Cancer Res. 2020 11 01; 26(21):5631-5637.
    View in: PubMed
    Score: 0.006
  33. Holowatyj AN, Washington KM, Salaria SN, Lieu CH, Idrees K, Eng C. Early-Onset Appendiceal Cancer Survival by Race or Ethnicity in the United States. Gastroenterology. 2020 10; 159(4):1605-1608.
    View in: PubMed
    Score: 0.006
  34. Serebriiskii IG, Connelly C, Frampton G, Newberg J, Cooke M, Miller V, Ali S, Ross JS, Handorf E, Arora S, Lieu C, Golemis EA, Meyer JE. Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients. Nat Commun. 2019 08 19; 10(1):3722.
    View in: PubMed
    Score: 0.005
  35. Capasso A, Lang J, Pitts TM, Jordan KR, Lieu CH, Davis SL, Diamond JR, Kopetz S, Barbee J, Peterson J, Freed BM, Yacob BW, Bagby SM, Messersmith WA, Slansky JE, Pelanda R, Eckhardt SG. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. J Immunother Cancer. 2019 02 08; 7(1):37.
    View in: PubMed
    Score: 0.005
  36. Emens LA, Davis SL, Oliver SCN, Lieu CH, Reddy A, Solomon S, He L, Morley R, Fassò M, Pirzkall A, Patel H, O'Hear C, Ferrara D. Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis. JAMA Ophthalmol. 2019 01 01; 137(1):96-100.
    View in: PubMed
    Score: 0.005
  37. Davis SL, Eckhardt SG, Diamond JR, Messersmith WA, Dasari A, Weekes CD, Lieu CH, Kane M, Choon Tan A, Pitts TM, Leong S. A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer. Oncologist. 2018 12; 23(12):1409-e140.
    View in: PubMed
    Score: 0.005
  38. Dotan E, Cohen SJ, Starodub AN, Lieu CH, Messersmith WA, Simpson PS, Guarino MJ, Marshall JL, Goldberg RM, Hecht JR, Wegener WA, Sharkey RM, Govindan SV, Goldenberg DM, Berlin JD. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. J Clin Oncol. 2017 Oct 10; 35(29):3338-3346.
    View in: PubMed
    Score: 0.005
  39. Amini A, Jones BL, Stumpf P, Leong S, Lieu CH, Weekes C, Davis SL, Messersmith WA, Purcell WT, Ghosh D, Schefter T, Goodman KA. Patterns of Care for Locally Advanced Pancreatic Adenocarcinoma Using the National Cancer Database. Pancreas. 2017 08; 46(7):904-912.
    View in: PubMed
    Score: 0.005
  40. Stumpf PK, Amini A, Jones BL, Koshy M, Sher DJ, Lieu CH, Schefter TE, Goodman KA, Rusthoven CG. Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis. Cancer. 2017 Sep 01; 123(17):3402-3409.
    View in: PubMed
    Score: 0.005
  41. Chapman BC, Hosokawa P, Henderson W, Paniccia A, Overbey DM, Messersmith W, Lieu C, Stiegmann GV, Schulick RD, Gajdos C. Impact of neoadjuvant chemoradiation on perioperative outcomes in patients with rectal cancer. J Surg Oncol. 2017 Jun; 115(8):1033-1044.
    View in: PubMed
    Score: 0.004
  42. Weekes CD, Lamberts LE, Borad MJ, Voortman J, McWilliams RR, Diamond JR, de Vries EG, Verheul HM, Lieu CH, Kim GP, Wang Y, Scales SJ, Samineni D, Brunstein F, Choi Y, Maslyar DJ, Colon-Otero G. Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer. Mol Cancer Ther. 2016 Mar; 15(3):439-47.
    View in: PubMed
    Score: 0.004
  43. Kessler ER, Eckhardt SG, Pitts TM, Bradshaw-Pierce EL, O'byrant CL, Messersmith WA, Nallapreddy S, Weekes C, Spratlin J, Lieu CH, Kane MA, Eppers S, Freas E, Leong S. Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers. Invest New Drugs. 2016 Apr; 34(2):176-83.
    View in: PubMed
    Score: 0.004
  44. Arcaroli JJ, Tai WM, McWilliams R, Bagby S, Blatchford PJ, Varella-Garcia M, Purkey A, Quackenbush KS, Song EK, Pitts TM, Gao D, Lieu C, McManus M, Tan AC, Zheng X, Zhang Q, Ozeck M, Olson P, Jiang ZQ, Kopetz S, Jimeno A, Keysar S, Eckhardt G, Messersmith WA. A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer. Int J Cancer. 2016 Jan 01; 138(1):195-205.
    View in: PubMed
    Score: 0.004
  45. Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong D, Hoff P, Tran H, Menter DG, Heymach J, Overman M, Kopetz S. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer. 2015 Mar 17; 112(6):1088-97.
    View in: PubMed
    Score: 0.004
  46. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011 Oct 15; 117(20):4623-32.
    View in: PubMed
    Score: 0.003
  47. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010 Jan 20; 28(3):453-9.
    View in: PubMed
    Score: 0.003
  48. O'Bryant CL, Lieu CH, Leong S, Boinpally R, Basche M, Gore L, Leonardi K, Schultz MK, Hariharan S, Chow L, Diab S, Gibbs A, Eckhardt SG. A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state. Cancer Chemother Pharmacol. 2009 Feb; 63(3):477-89.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)